DEBIOPHARM
27.8.2024 14:01:31 CEST | Business Wire | Press release
Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, announced today their participation in the 2024 World AMR conference from September 5th-6th in Philadelphia, Pennsylvania, USA. For the last decade, Debiopharm has been committed to developing new antimicrobials for patients by conducting research on a novel class of antibiotics that target hard-to-treat infections, caused by WHO priority pathogens. Now in its third year of sponsoring World AMR, Debiopharm is proud to support the conference’s mission to unite key decision-makers in AMR from international government bodies, policy organizations, and the healthcare sector to meet, discuss, and formulate initiatives to tackle the emerging threat of AMR effectively.
This year, Debiopharm’s Head of Global Value & Access, Jennifer Quinn, will present within the Impact, Policy and Awareness Track and lead a roundtable discussion on how to move the needle on fair reimbursement for antibiotics. Focused on actionable ways to leverage current reimbursement models, Jennifer’s presentation will outline a tangible framework for payer negotiations and discuss evidence needs for products that will reach the market before ‘pull incentives’ become available.
“We’re looking forward to open discussions and networking opportunities with public organizations and other infectious disease industry experts to put into place practical solutions to combat the reimbursement challenged that help to fuel AMR.” – Jennifer Quinn, Head of Global Value & Access.
World AMR 2023 Session details |
Congress agenda |
Speaker |
Presentation Sept. 5th 11:20AM EST
|
How can current reimbursement models be leveraged while waiting for 'pull incentives'? |
Jennifer Quinn, Head of Global Value & Access |
Roundtable discussion Sept. 5th 01:30PM EST
|
What data is needed to fit current payer evidence requirements and how can we generate it? |
Jennifer Quinn, Head of Global Value & Access |
About afabicin
Afabicin (Debio 1450) is Debiopharm’s first-in-class FabI inhibitor, selectively targeting Staphylococcus’ essential bacterial fatty acid biosynthesis pathway. Afabicin is active against Staphylococcus spp., of which methicillin-resistant Staphylococcus aureus (MRSA) strains are high on the WHO global priority pathogen list and deemed a “serious threat” by the CDC. Afabicin can be administered orally or intravenously. Promising results have been obtained in a comparative double-blind Phase 2 trial with afabicin in acute bacterial skin and skin structure infections. Currently, a global Phase 2 trial in bone and joint infections is being conducted, comparing afabicin to standard antibiotics.
About Debio 1453
Analogous to afabicin, the preclinical compound Debio 1453 is a potential first-in-class pathogen-specific drug targeting the essential bacterial fatty acid biosynthesis pathway. Debio 1453 has been developed as an oral drug with activity against. Neisseria gonorrhoeae, the bacteria causing the sexually transmitted disease gonorrhea. Untreated gonorrhea can cause serious and permanent health issues including infertility, ectopic pregnancy, long-term pelvic/abdominal pain, blindness in newborns and in rare cases also have a lethal outcome.
Debiopharm’s fight against antimicrobial resistance
Debiopharm, an innovation-focused, Swiss biopharmaceutical company is one of the few privately owned companies developing novel class antibiotics to combat hard-to-treat infections. Through their unique partnership-based business model, the company is advancing pathogen-specific antibiotics from early stage through phase II clinical research with afabicin, specifically targeting staphylococci. As a result of high selectivity, FabI inhibitors specifically target selected pathogens, and potentially preserve intestinal microbiota. Debiopharm’s FabI inhibitors meet all four WHO 2020 innovation criteria: new chemical class, new target, new mode of action and no cross-resistance to other antibiotic classes.
For more information, please visit www.debiopharm.com
We are on X. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews
Sources
- Antimicrobial Resistance Collaborators. (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet; 399(10325): P629-655.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827078184/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thermochemical Energy Storage Leader Redoxblox Rebrands as Tempo31.3.2026 09:00:00 CEST | Press release
Breaking the heat barrier: Tempo advances towards commercial rollout of continuously delivered electrified industrial heat at up to 1,200°C Redoxblox, a leader in thermochemical energy storage (TCES) on a mission to electrify the world with technology that shifts the power dynamic, today announced its rebrand to Tempo. The new identity marks the company’s transition from technology development to the commercial scaling of its breakthrough electrified heat platform. The rebrand, developed in partnership with renowned creative agency Red Antler, aligns Tempo’s strategic identity with its unique ability to meet the rigorous demands of heavy industry. The name Tempo is a nod to three core pillars of the company’s value proposition: Temperature leadership, the time-shifting of energy, and the pace of both continuous industrial heat delivery and rapid innovation. “As we move from technical validation toward large-scale commercial rollout, our brand must reflect the scale of the challenge we
Allshares Acquires Technology Company Amalia to Accelerate Innovation in Ownership and Incentive Management31.3.2026 09:00:00 CEST | Press release
Allshares, a global equity and ownership management platform, today announced the acquisition of Amalia, a France-based company specializing in sales commission and performance management software. The acquisition strengthens Allshares' platform, adding a sophisticated, rules-based engine that expands and enhances its end-to-end ownership offering. Founded in 2020, Amalia was built technology-first. Its software is centered on a powerful rules engine that enables intuitive compensation plan design, giving organizations the flexibility to model incentive structures in a fully self-service environment, unlocking new possibilities for incentive management at scale. Supporting more than 40 organizations, including Nespresso, TheFork, and Rakuten, Amalia provides real-time visibility into performance and incentive data, enabling companies to operate complex compensation programs with greater control and efficiency. “From day one, our focus has been to bring clarity to performance-based comp
Schneider Electric Joins Thread Group Board of Directors31.3.2026 09:00:00 CEST | Press release
Global technology leader elevates its membership to drive the future of smart homes and commercial buildings The Thread Group, an industry alliance addressing IoT convergence, security, power, and architecture challenges, today announced that Schneider Electric has joined its Board of Directors. A member of the Thread Group since 2015, Schneider Electric will take a more active role in shaping the future of the Thread wireless networking protocol moving forward. This addition comes at a pivotal time for the organization, with Thread recently surpassing 1000 consumer products, and as we continue to see expansion into commercial markets. Thread 1.4 delivers significant benefits for commercial and industrial applications, including seamless communication, enhanced reliability, and performance in expansive IoT deployments. "The entire Thread Group will benefit from Schneider Electric’s deeper engagement in our efforts," said Vividh Siddha, President of Thread Group. "A dedicated member for
STV Group and Post-Quantum Successfully Trial World’s First Quantum-Resilient Drones31.3.2026 09:00:00 CEST | Press release
Partnership delivers quantum-resilient drone platform for NATO allies Technical breakthrough: first airborne deployment of Classic McEliece algorithm Combat-proven UAV systems integrated with Classic McEliece post-quantum cryptography (PQC) to secure unmanned operations against future quantum threats. STV Group a.s., a European defence technology integrator with platforms deployed in Ukraine and allied theatres, and Post-Quantum, the UK cybersecurity company, today announced successful testing of the world’s first quantum-safe drones for active deployment across allied theatres. As allied nations adapt to warfighting defined by autonomous systems and drones, the ability to futureproof secure communications between drones and their operators is of paramount importance. Drone swarms procured today may be stored and deployed in future operations years later. This dynamic requires drones manufactured today incorporate encryption that’s resistant to attack by both classical and quantum comp
Regnology Announces Next-Generation Ascend Platform with Agentic AI, Advancing the Future of Regulatory Reporting31.3.2026 08:00:00 CEST | Press release
Enhancements Extend to Regnology Supervisory Hub, accelerating the Straight‑Through‑Reporting (STR) vision Regnology, a global leading provider at the intersection of regulatory, risk, finance and supervisory technology, today announced the evolution of Ascend, the next‑generation Regnology platform. This landmark release introduces a powerful agentic AI layer to the Regnology platform and formally integrates the Regnology Supervisory Hub (RSH) into the Ascend ecosystem. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330254615/en/ Launched in late 2025, Ascend is the catalyst of Regnology’s Straight-Through-Reporting (STR) vision. The initial rollout empowered financial institutions with RRH Ascend delivering intelligent data governance for proactive quality assurance, predictive insights to anticipate regulatory demands, powerful automation to execute complex workflows, and contextual collaboration for seamless human ove
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom